Neogenomics Inc
NASDAQ:NEO

Watchlist Manager
Neogenomics Inc Logo
Neogenomics Inc
NASDAQ:NEO
Watchlist
Price: 16.39 USD 6.5% Market Closed
Market Cap: 2.1B USD
Have any thoughts about
Neogenomics Inc?
Write Note

Neogenomics Inc
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Neogenomics Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Neogenomics Inc
NASDAQ:NEO
Stock-Based Compensation
$32.1m
CAGR 3-Years
29%
CAGR 5-Years
27%
CAGR 10-Years
39%
Thermo Fisher Scientific Inc
NYSE:TMO
Stock-Based Compensation
$283m
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
10%
Danaher Corp
NYSE:DHR
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mettler-Toledo International Inc
NYSE:MTD
Stock-Based Compensation
$19.1m
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
4%
Agilent Technologies Inc
NYSE:A
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Neogenomics Inc
Glance View

Market Cap
2.1B USD
Industry
Life Sciences Tools & Services

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,000 full-time employees. The company went IPO on 2012-12-10. The firm operates through two segments: the Clinical Services Segment and the Pharma Services Segment. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research. The company offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. The company operates testing laboratories in United States, Europe and Asia.

NEO Intrinsic Value
12.26 USD
Overvaluation 25%
Intrinsic Value
Price

See Also

What is Neogenomics Inc's Stock-Based Compensation?
Stock-Based Compensation
32.1m USD

Based on the financial report for Sep 30, 2024, Neogenomics Inc's Stock-Based Compensation amounts to 32.1m USD.

What is Neogenomics Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
39%

Over the last year, the Stock-Based Compensation growth was 44%. The average annual Stock-Based Compensation growth rates for Neogenomics Inc have been 29% over the past three years , 27% over the past five years , and 39% over the past ten years .

Back to Top